AZK to lower Crestor price voluntarily

Published: 2008-12-24 06:59:00

Updated: 2008-12-24 06:59:00

The Health Insurance Review and Assessment Service said on December 19 that it has finalized the assessment of economic effectiveness over Crestor, cholesterol-lowering drug to treat the clogging of arteries, following AstraZeneca’s written notice that they would voluntarily reduce Crestor price ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK